GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

mezagitamab   Click here for help

GtoPdb Ligand ID: 10609

Synonyms: TAK-079 | TAK079
Immunopharmacology Ligand
Compound class: Antibody
Comment: Mezagitamab (TAK-079) is a humanized, IgG1, cell-depleting anti-CD38 monoclonal antibody [7-8]. Anti-CD38 therapeutics were primarily developed as treatments for multiple myeloma [9], but have subsequently been discovered to offer potential in solid tumours and autoimmune diseases [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
TAK‐079 was advanced to evaluation in clinical trial to determine efficacy of anti-CD38 treatment in the antibody-mediated autoimmune disease myasthenia gravis [1]. Additional trials were undertaken for multiple myeloma (MM), systemic lupus erythematosus (SLE) [6], and primary immune thrombocytopenia (ITP). The FDA granted TAK‐079 orphan designation for the treatment of MM in January 2019, but this was later withdrawn. As of April 2026, FDA orphan designations were in place for the treatment of myasthenia gravis and ITP.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04278924 A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia Phase 2 Interventional Takeda 5
NCT03439280 A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) Phase 1/Phase 2 Interventional Takeda Based on results from this study the decision was made to cease development of mezagitamab in MM. 4